Stock Details
BIIB is Biogen Inc.'s stock. Stock exchange NasdaqGS (Currency USD). Average price in 50 days is 292.21$. Average daily volumn in 3 months 907.8k. Market cap 43.23B

Stock symbol : BIIB. Exchange : NasdaqGS. Currency : USD
Lastest price : 298.66$. Total volume : 945.60k. Market state CLOSED
Click reload if you want to check the lastest price on market!!!

Biogen Inc. (BIIB)
Last Price

Previous Close297.13
Day Range295.34-299.11
Bid293.55 x 800
Ask300.00 x 800
Average Volume907.8k
Market Cap43.23B
52 Week Range188.54-319.74
Trailing P/E14.11
Foward P/E18.31
Dividend (Yield %)N/A
Ex-Dividend DateN/A

Financial Details

According to Biogen Inc.'s financial reports the company's revenue in 2022 were 10.17B an decrease(0%) over the years 2021 revenue that were of 10.98B. In 2022 the company's total earnings were 3.05B while total earnings in 2021 were 1.56B( +200%).

Loading ...


Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases in the United States, Europe, Germany, Asia, and internationally. The company offers TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; ADUHELM to treat Alzheimer's disease; FUMADERM to treat plaque psoriasis; BENEPALI, an etanercept biosimilar referencing ENBREL; IMRALDI, an adalimumab biosimila... r referencing HUMIRA; FLIXABI, an infliximab biosimilar referencing REMICADE; and BYOOVIZ, a ranibizumab biosimilar referencing LUCENTIS. It also provides RITUXAN for treating non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL), rheumatoid arthritis, two forms of ANCA-associated vasculitis, and pemphigus vulgaris; RITUXAN HYCELA for non-Hodgkin's lymphoma and CLL; GAZYVA to treat CLL and follicular lymphoma; OCREVUS for relapsing MS and primary progressive MS; LUNSUMIO to treat relapsed or refractory follicular lymphoma; glofitamab for non-Hodgkin's lymphoma; and other anti-CD20 therapies. In addition, the company is developing various products for the treatment of MS, Alzheimer's disease and dementia, neuromuscular disorders, Parkinson's disease and movement disorders, neuropsychiatry, immunology related diseases, neurovascular disorders, genetic neurodevelopmental disorders, and biosimilars, which are under various stages of development. Biogen Inc. has collaboration and license agreements with Acorda Therapeutics, Inc.; Alkermes Pharma Ireland Limited; Denali Therapeutics Inc.; Eisai Co., Ltd.; Genentech, Inc.; Neurimmune SubOne AG; Ionis Pharmaceuticals, Inc.; Samsung Bioepis Co., Ltd.; Sangamo Therapeutics, Inc.; and Sage Therapeutics, Inc. The company was founded in 1978 and is headquartered in Cambridge, Massachusetts.

Market Cap:
Total Assets:
Total Cash:

News about "Biogen Inc."


Biogen Inc. (NASDAQ:BIIB) is favoured by institutional owners who hold 88% of the company

Source from : YAHOO!Finance - 17 hours ago

The top 15 shareholders own 51% of the company If you want to know who really controls Biogen Inc. ( NASDAQ:BIIB ), then you'll have to look at the makeup of its share registry. The group holding the ...See details»


3 Reasons to Buy Biogen Stock (and 1 to Sell)

Source from : The Motley Fool on MSN - 17 days ago

The stock has been rallying but how it performs from here will likely depend on the fate of its Alzheimer's treatment, Leqembi.See details»

Biogen Inc. (BIIB) Up 4.7% Since Last Earnings Report: Can It Continue?

Source from : YAHOO!Finance - 4 days ago

Biogen Inc. (BIIB) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.See details»

Biogen Inc

Source from : Reuters - 1 year ago

Future of Healthcategory Eisai, Biogen Alzheimer's drug Leqembi would cost US Medicare up to $5 bln a year, study finds May 12, 2023 Future of Healthcategory After weight loss, Alzheimer's may be ...See details»

Biogen Inc Down 3.70% To $282.20 After Earnings

Source from : - 1 month ago

Biogen Inc (BIIB) said before open Tuesday that it broke even in quarter one 2023. In the same quarter a year ago, the company earned $3.62 per share on revenue of $2.5 billion. The stock is down ...See details»

Biogen Inc.'s financial results 2021

Source from : Statista - 1 year ago

You may also be interested in... Biogen's top products based on revenue 2020-2022 Biogen's top products based on revenue 2020-2022 Biogen's revenues by type and region 2022 Biogen's revenues by ...See details»

Biogen Inc. (BIIB) Beats Q1 Earnings and Revenue Estimates

Source from : Nasdaq - 1 month ago

Biogen Inc. (BIIB) came out with quarterly earnings of $3.40 per share, beating the Zacks Consensus Estimate of $3.25 per share. This compares to earnings of $3.62 per share a year ago.See details»

Biogen Inc. (NASDAQ:BIIB) Q1 2023 Earnings Call Transcript

Source from : Insider Monkey - 28 days ago

The way I would think about it is and the way I look at Biogen is I think Zuranolone actually is a product that can actually contribute faster to our sales growth in 2024. And I do think that one ...See details»

Biogen Inc.: Health Canada Accepts New Drug Submission for Lecanemab as Treatment for Early Alzheimer's Disease

Source from : Finanznachrichten - 14 days ago

Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") and Biogen Inc. (Nasdaq: BIIB, Corporate headquarters: Cambridge, Massachusetts ...See details»

Is Biogen Inc.'s (NASDAQ:BIIB) Recent Stock Performance Influenced By Its Fundamentals In Any Way?

Source from : Yahoo News UK - 25 days ago

Biogen's (NASDAQ:BIIB) stock is up by a considerable 12% over the past month. As most would know, fundamentals are what usually guide market price movements over the long-term, so we decided to look ...See details»

New Suit - Contract

Source from : Law - 24 days ago

Counsel have not yet appeared for Biogen. The case is 2:23-cv-02491, Teva Pharmaceuticals USA, Inc. v. Biogen International Gmbh.See details»

Biogen Inc.

Source from : Wall Street Journal - 1 month ago

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...See details»

Q1 2023 Biogen Inc Earnings Call

Source from : Yahoo Finance - 1 month ago

Charles E. Triano; Senior VP & Head of IR; Biogen Inc. Christopher A. Viehbacher; President, CEO & Director; Biogen Inc. Michael R. McDonnell; Executive VP & CFO; Biogen Inc. Priya Singhal; Executive ...See details»

Biogen Inc. (NASDAQ:BIIB) is favoured by institutional owners who hold 87% of the company

Source from : Yahoo Style UK - 1 month ago

Institutions' substantial holdings in Biogen implies that they have significant influence over the company's share price 51% of the business is held by the top 16 shareholders Recent sales by insiders ...See details»